Photo: 颐园居 | CC BY-SA 4.0 | Wikimedia Commons
Supreme Court Lets Medicare Drug Price Negotiation Program Move Forward
The Supreme Court on Monday, May 18, 2026, rejected appeals from drug manufacturers that aimed to block Medicare drug price negotiations, clearing the way for the federal program to move forward.[1]
The high court left intact federal appeals court rulings from Philadelphia that had dismissed the manufacturers' claims against the program.[1] Manufacturers had argued the law exceeded government authority and asked the high court to intervene.[1]
The negotiation program was created by the 2022 Inflation Reduction Act. It has produced negotiated prices for 25 Medicare-covered drugs so far, and a third round announced in January will bring the total to 40.
Show source details & analysis (1 source)
📌 Key Facts
- On Monday, May 18, 2026, the Supreme Court rejected appeals from drug manufacturers challenging Medicare drug price negotiations.
- The Court left intact federal appeals court rulings from Philadelphia that had dismissed the manufacturers’ claims.
- The negotiation program, created by the 2022 Inflation Reduction Act, has so far produced negotiated prices for 25 Medicare-covered drugs, with a third round announced in January to bring the total to 40.
📰 Source Timeline (1)
Follow how coverage of this story developed over time